Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 91 citing articles:

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, et al.
Hepatology (2023) Vol. 77, Iss. 5, pp. 1797-1835
Open Access | Times Cited: 1159
Global epidemiology of cirrhosis — aetiology, trends and predictions
Daniel Q. Huang, Norah A. Terrault, Frank Tacke, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 6, pp. 388-398
Open Access | Times Cited: 375
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 314
The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review
Rodrigo Zamignan Carpi, Sandra Maria Barbalho, Kátia Portero Sloan, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8805-8805
Open Access | Times Cited: 88
Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Monica A. Tincopa, Rohit Loomba
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 7, pp. 660-670
Closed Access | Times Cited: 84
Clinical Trial Landscape in NASH
Stephen A. Harrison, Rohit Loomba, Julie Dubourg, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2001-2014
Closed Access | Times Cited: 74
Noninvasive Assessment of Liver Fibrosis in NAFLD
Arun J. Sanyal, Laurent Castéra, Vincent Wai‐Sun Wong
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2026-2039
Closed Access | Times Cited: 71
Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis
Daniel Q. Huang, Nabil Noureddin, Veeral Ajmera, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 9, pp. 829-836
Open Access | Times Cited: 71
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 59
Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis
Arun J. Sanyal, Sudha S. Shankar, Katherine P. Yates, et al.
Nature Medicine (2023) Vol. 29, Iss. 10, pp. 2656-2664
Open Access | Times Cited: 55
NASH drug treatment development: challenges and lessons
Herbert Tilg, Christopher D. Byrne, Giovanni Targher
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 10, pp. 943-954
Open Access | Times Cited: 48
Metabolic dysfunction-associated steatotic liver disease in adults
Daniel Q. Huang, Vincent Wai‐Sun Wong, Mary E. Rinella, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access | Times Cited: 2
Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC
Suzanne R. Sharpton, Rohit Loomba
Hepatology (2023) Vol. 78, Iss. 6, pp. 1896-1906
Open Access | Times Cited: 26
CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population
Eduardo Vilar‐Gómez, Raj Vuppalanchi, Samer Gawrieh, et al.
Hepatology (2023) Vol. 77, Iss. 4, pp. 1241-1252
Closed Access | Times Cited: 25
Interpretation, Reporting, and Clinical Applications of Liver MR Elastography
Guilherme Moura Cunha, Boyan Fan, Patrick J. Navin, et al.
Radiology (2024) Vol. 310, Iss. 3
Closed Access | Times Cited: 13
Monitoring disease progression in metabolic dysfunction‐associated steatotic liver disease
Nabil Noureddin, Nedret Copur‐Dahi, Rohit Loomba
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Closed Access | Times Cited: 13
Envisioning how to advance the MASH field
Alina M. Allen, Zobair M. Younossi, Anna Mae Diehl, et al.
Nature Reviews Gastroenterology & Hepatology (2024)
Closed Access | Times Cited: 13
The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease
Francisco Barrera, Javier Uribe, Nixa Olvares, et al.
Annals of Hepatology (2024) Vol. 29, Iss. 4, pp. 101501-101501
Open Access | Times Cited: 9
The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes
Lana Bridi, Saaket Agrawal, Kaleb Tesfai, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 3, pp. 369-377
Closed Access | Times Cited: 9
Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
Nobuharu Tamaki, Takefumi Kimura, Shun‐ichi Wakabayashi, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 8, pp. 1033-1041
Closed Access | Times Cited: 9
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
Jung Hwan Yu, Yong Sang Lee, Seung Up Kim
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S136-S149
Open Access | Times Cited: 33
Point-of-Care Noninvasive Prediction of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease
Mònica Pons, Jesús Rivera‐Esteban, Mang Ma, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 8, pp. 1637-1645.e9
Closed Access | Times Cited: 20
Global Prevalence of Advanced Liver Fibrosis and Cirrhosis in the General Population: A Systematic Review and Meta-analysis
Mohammad Zamani, Shaghayegh Alizadeh‐Tabari, Veeral Ajmera, et al.
Clinical Gastroenterology and Hepatology (2024)
Closed Access | Times Cited: 7
KASL Clinical Practice Guidelines for Noninvasive Tests to Assess Liver Fibrosis in Chronic Liver Disease
Mi Na Kim, Ji Won Han, Jihyun An, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. Suppl, pp. S5-S105
Open Access | Times Cited: 6
Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
Terry Cheuk‐Fung Yip, Fei Lyu, Huapeng Lin, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S171-S183
Open Access | Times Cited: 26
Page 1 - Next Page

Scroll to top